Abstract
The development of efficacious and safe post transcriptional gene silencing (PTGS) agents is a challenging scientific endeavor that embraces “biocomplexity” at many levels. The target mRNA exhibits a level of structural complexity that profoundly limits annealing of PTGS agents. PTGS agents are macromolecular RNAs that must be designed to fold into catalytically active structures able to cleave the target mRNA. Pushing into and beyond the biological complexity requires new technologies for high throughput screening to efficiently and rapidly assess a set of biological and experimental variables engaged in RNA drug discovery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdelmaksoud H, Yau EH, Zuker M et al (2009) Development of lead hammerhead ribozyme candidates against human rod opsin for retinal degeneration therapy. Exp. Eye Res 88:859–879
Allawi HT, Dong F, Ip HS et al (2001) Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase. RNA 7:314–327
Boon CJF, den Hallander AI, Hoyng CB et al (2008) The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. Prog Ret Eye Res 27:213–225
Butler MC, Sullivan JM (2010) A novel real-time in vivo mouse retinal imaging system. Invest Ophthalmol Vis Sci 51:3103
Den Hollander AI, Black A, Bennet J et al (2010). Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 120: 3042–3053
Ding Y, Chan CY, Lawrence CE (2004) Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res 32 (supp):W135-W141
Farjo R, Skaggs J, Quiambao AB et al (2006) Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One 1:e38
Flannery JG, Zolotukhin S, Vaquero MI et al (1997) Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94:6916–6921
Ho SP, Bao Y, Lesher T, Malhotra R et al (1998) Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 16:56–63
Khvorova A, Lescoute A, Westhof E et al (2003) Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nature Struct Biol 10: 708–712
Koseki S, Tanabe T, Tani K et al (1999) Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol 73:1868–1877
Lieber A, Strauss M (1995) Selection of efficient cleavage sites in target mRNAs by using a ribozyme expression library. MolCell. Biol 15:540–551
Mathews DH, Burkard ME, Freier SM et al (1999) Predicting oligonucleotide affinity to nucleic acid targets. RNA 5:1458–1469
Stage-Zimmermann TK, Uhlenbeck OC (1998) Hammerhead ribozyme kinetics. RNA 4:875–889
Sullivan JM, Taggart RT (2007) Novel and enhanced approaches to determined local mRNA accessibility. Invest Ophthalmol Vis Sci 48:4605
Yau EH, Sullivan JM (2007) High throughput cellular screening for ribozyme development against arbitrary mRNA targets. Invest Ophthalmol Vis Sci 48:1681
Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406–3415
Acknowledgments
We thank the National Eye Institute (R01 EY13433, PI: Sullivan) (R24 EY016662, PI: M Slaughter), the Veterans Administration (Merit Grant 1I01BX000669-01), an Unrestricted grant from Research to Prevent Blindness, and a grant from the Oishei Foundation (Buffalo, NY).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this paper
Cite this paper
Sullivan, J.M., Yau, E.H., Taggart, R.T., Butler, M.C., Kolniak, T.A. (2012). Relieving Bottlenecks in RNA Drug Discovery for Retinal Diseases. In: LaVail, M., Ash, J., Anderson, R., Hollyfield, J., Grimm, C. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 723. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0631-0_20
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0631-0_20
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-0630-3
Online ISBN: 978-1-4614-0631-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)